SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 20, 2003
HAEMONETICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Massachusetts 1-10730 04-288 2273
------------- ------- -----------
(State or other jurisdiction of (Commission File (IRS Employer
incorporation or organization) Number) Identification Number)
400 Wood Road
Braintree, MA 02184
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code (781) 848-7100
Item 5. Other Events and Regulation FD Disclosure
- ---------------------------------------------------
On August 20, 2003, Haemonetics Corporation (the "Company"), announced the
appointments of Peter M. Allen and Brian Concannon, respectively, as
Presidents of its newly created Donor and Patient Divisions.
Item 7. Financial Statements and Exhibits.
- --------------------------------------------
(c) Exhibits.
---------
99.1 Press Release of the Company dated August 20, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
Date: August 20, 2003 By: s/Brad Nutter
--------------- -------------------------------
Brad Nutter, President
and Chief Executive Officer
3
EXHIBIT 99.1
FOR RELEASE: CONTACT:
Date: August 20, 2003 Lisa Lopez
Time: 9:30 am Tel. (781) 356-9457
Alternate Tel. (617) 320-2401
fallon@haemonetics.com
HAEMONETICS APPOINTS EXECUTIVE LEADERSHIP OF NEW OPERATING DIVISIONS
PETER ALLEN HIRED AS PRESIDENT, DONOR DIVISION
BRIAN CONCANNON HIRED AS PRESIDENT OF PATIENT DIVISION
BRAINTREE, MA, August 20, 2003 - Today Haemonetics Corporation announced the
appointments of Peter M. Allen and Brian Concannon, respectively, as
Presidents of the Company's newly created Donor and Patient Divisions. The
Donor Division will deliver products and services to blood collectors
worldwide. The Patient Division will deliver products and services to
hospitals worldwide.
Mr. Allen has over twenty years experience in health care and medical
products. He was employed in numerous sales, marketing and management
positions during his fourteen year career at Baxter International including
as Director of the Marketing Distribution Division. From 1998 - 2001, Mr.
Allen was Vice President of Pharmacy Services, then Oncology Business at
Syncor International. Most recently, he was Vice President with The Athena
Group, a merchant banking group engaged exclusively in strategic financing
and advisory services to the global healthcare industry. Mr. Allen is a
1981 finance graduate of Lehigh University.
Mr. Concannon has eighteen years sales, marketing and operations management
experience of increasing responsibility at American Hospital Supply
Corporation, Baxter Healthcare Corporation, Allegiance Healthcare, and
Cardinal Health Medical Products and Services. Most recently, he was
President of Cardinal's Northeast Region, with profit and loss
responsibility for a $1.3 billion business consisting of 10 facilities and
1,100 employees in the 12 northeast states. Mr. Concannon is a 1979
graduate of the U.S. Military Academy at West Point, with a B.S. degree,
concentration in engineering.
Brad Nutter, Haemonetics President and CEO commented, "I have known these
executives for most of their accomplished careers. I'm proud and delighted
that Haemonetics has attracted such broad based executives to our leadership
team."
Haemonetics will be presenting in late September at conferences sponsored by
UBS Warburg in New York City and Sidoti & Company in San Francisco.
Haemonetics (NYSE: HAE) is a global company engaged in the design,
manufacture and worldwide marketing of automated blood processing systems.
These systems address important medical markets: surgical blood salvage,
blood component collection, plasma collection, and blood component safety.
To learn more about Haemonetics' products and markets, visit the Company's
web site at http://www.haemonetics.com.
4